MOLN Kronos AI forecast
A 30-trading-day price forecast for Molecular Partners AG American Depositary Shares (MOLN) from Kronos AI, an open-source foundation model trained on candlestick charts.
Kronos AI's median forecast puts Molecular Partners AG American Depositary Shares at $4.01 on 2026-12-08, +5.2% from the last close of $3.81 on 2026-10-27. Eight out of ten sampled paths end between $3.92 and $4.13, and 8 of the 8 paths finish above today's price.
Forecast path
median, with the 10–90% band of the sampled pathsOpen the interactive forecast → Full analysis of MOLN
The forecast, week by week
| Date | Median | Low (10%) | High (90%) |
|---|---|---|---|
| 2026-11-03 | $3.76 | $3.61 | $3.92 |
| 2026-11-10 | $3.90 | $3.80 | $4.13 |
| 2026-11-17 | $3.97 | $3.78 | $4.30 |
| 2026-11-24 | $4.00 | $3.85 | $4.27 |
| 2026-12-01 | $4.04 | $3.97 | $4.16 |
| 2026-12-08 | $4.01 | $3.92 | $4.13 |
What is Kronos AI?
Kronos is an open-source foundation model for financial candlesticks, pre-trained on K-line data from more than 45 exchanges. Gnzub runs it on each stock's last 120 daily bars and samples several possible futures, so the forecast is a range of outcomes rather than one confident line. It is a statistical model, not an analyst: it reads price patterns only and knows nothing about news, earnings or the business.
Questions
- What is the Kronos AI forecast for MOLN?
- Kronos AI's median forecast for MOLN is $4.01 in 30 trading days, +5.2% from the last close, with a 10–90% range of $3.92 to $4.13.
- Is the MOLN Kronos forecast a buy or sell signal?
- No. It is the output of a statistical model that reads price history only. It is not investment advice, and the range shows how uncertain the model is.
- How often is the forecast updated?
- The forecasts are regenerated regularly; this one starts from the close of 2026-10-27.
Kronos forecasts for similar companies
- AMGN — Amgen Inc.
- GILD — Gilead Sciences Inc.
- MRNA — Moderna Inc.
- ARGX — argenx SE American Depositary Shares
- RVMD — Revolution Medicines Inc.
- BIIB — Biogen Inc.